Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna Inc.

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Moderna, with a price target of $41.00. Meacham covers the Healthca...

Citi Sticks to Their Hold Rating for Moderna (MRNA)

Barclays analyst Eliana Merle maintained a Hold rating on Moderna today and set a price target of $48.00. According to TipRanks, Merle is a 2-star ...

Barclays Sticks to Its Hold Rating for Moderna (MRNA)

Analysts fell to the sidelines weighing in on AbbVie (ABBV) and Moderna (MRNA) with neutral ratings, indicating that the experts are neither bullis...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Moderna (MRNA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV) and Moderna (MRNA). AbbVie (ABBV) J....

Analysts Conflicted on These Healthcare Names: AbbVie (ABBV) and Moderna (MRNA)

Moderna ( ($MRNA) ) has risen by 22.69%. Read on to learn why. Moderna’s shares have surged 22.69% over the past week, as investors warmed to the c...

Moderna Stock Jumps as Pipeline Hype Outruns Wall Street

Citi Sticks to Its Hold Rating for Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Scienture Holdings (SCNX). Moderna (MRNA) Will...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) an...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)

Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. (MRNA) is running a Phase 2 trial called “A Study of mRNA-1345...

Moderna’s Maternal RSV Vaccine Study Reaches Completion: What Investors Should Watch

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday. The company’s shares closed yesterday at $47.73. Breen covers the H...

Moderna (MRNA) Gets a Hold from Bernstein

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Glaukos (GKOS). Moderna (MRNA) William Blair a...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Glaukos (GKOS)

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) has updated a key early‑stage study of its cytomegalovirus, or ...

Moderna’s CMV Vaccine Study Update: What mRNA‑1647 Progress Means for MRNA Investors

Barclays analyst Eliana Merle maintained a Hold rating on Moderna today and set a price target of $48.00. According to TipRanks, Merle is a 3-star ...

Barclays Sticks to Their Hold Rating for Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Mediwound (MDWD). Moderna (MRNA) In a report r...

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Mediwound (MDWD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Labcorp Holdings (LH), Moderna (MRNA) and Celcuity...

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC)

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Moderna yesterday and set a price target of $32.00. According to TipR...

Moderna (MRNA) Gets a Sell from Bank of America Securities

Moderna ($MRNA) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Observer-blind, Dose-finding, Placeb...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRNA	$60.42	-0.95%	5.14M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRNA	$60.42	-1.0%	5.14M
3
4
5
6

MRNA

MRNA

Get Moderna Inc. Data in Excel

Get Moderna Inc. Data in Excel